Outcome evaluations in gout

Journal of Rheumatology

Volumn 34, Issue 6, 2007, Pages 1381-1385

  Schumacher, H Ralph ^a   Taylor, William ^b   Joseph Ridge, Nancy ^c   Perez Ruiz, Fernando ^d   Chen, Lan X ^e   Schlesinger, Naomi ^f   Khanna, Dinesh ^g   Furst, Daniel E ^h   Becker, Michael A ⁱ   Dalbeth, Nicola ^j   Edwards, N Lawrence ^k  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c TAP Pharmaceuticals   (United States)

^d HOSPITAL DE CRUCES   (Spain)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j UNIVERSITY OF AUCKLAND   (New Zealand)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Gout; Omeract; Outcomes; Uric acid

Indexed keywords

ALLOPURINOL; COLCHICINE; FEBUXOSTAT; URIC ACID;

CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; DELPHI STUDY; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; FUNCTIONAL STATUS; GOUT; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; ULTRASOUND; VALIDATION PROCESS;

ACUTE DISEASE; CHRONIC DISEASE; DELPHI TECHNIQUE; DISABILITY EVALUATION; GOUT; HEALTH STATUS; HUMANS; INTERNATIONAL COOPERATION; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS;

EID: 34250205285     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Schumacher HR, Edwards NL, Perez-Ruiz F, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-5.
2. Grainger R, Harrison AA, Taylor WJ. Preliminary identification of potential items for a definition of "gout flare" using Delphi methodology [abstract]. Arthritis Rheum 2005; 52 Suppl:S105.
3. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum 2005;52:916-23.
4. Becker MA, Schumacher HR, Wortmann RL, et al. Reduction in gout flares in subjects with chronic gout treated with febuxostat or allopurinol for 52-weeks: FACT trial [abstract]. Arthritis Rheum 2005;52 Suppl:S108.
5. Schumacher HR, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005;32:2368-72.
6. Wortmann RL, Schumacher HR, Becker MA, et al. Reduction in tophus size in subjects with chronic gout treated with febuxostat or allopurinol for 52 weeks - FACT trial [abstract]. Arthritis Rheum 2005;52 Suppl:S108.
7. Perez-Ruiz F, Martin JI, Canteli B, Sole JMN. Ultrasonography (US) is as useful as magnetic resonance imaging (MRI) for the evaluation of deep periarticular tophi in chronic gout [abstract]. Arthritis Rheum 2005;52 Suppl:S106.
8. Perez-Ruiz F, Martin JI. Serum urate levels correlate with changes in tophi measured with US during urate-lowering therapy. Rheumatol Clin 2006;2 Suppl:11.
9. Steinbrocker O. Prognosis for employability in the major arthritides rheumatoid arthritis, osteoarthritis and gout. Pa Med 1969;72:82-5.
10. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
11. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis - A three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
12. Wolfe F, Hawley DF. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17.
13. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
14. Osterhaus JT, Patel P, Palo WA, Bakst A, Joseph-Ridge N. Patient-reported outcomes associated with gout: baseline results from two clinical trials [abstract]. Arthritis Rheum 2005;52 Suppl:S401.
15. Schumacher HR, Boice JA, Daikh DI, et al. Randomized double-blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:488-92.
16. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum 2004;50:598-600.
17. Schumacher HR, Chen LX, Kwan-Morley J, Malik A, Dinnella JE, Kwoh CK. Validation of medical record gout diagnoses for research using cases in the VA database (abstract). Arthritis Rheum 2006;54 Suppl:S644.